Santarus and Pharming Announce Oral Presentations of Retrospective Analyses of Data from RHUCIN Clinical Program at World Allergy Congress

Santarus, Inc.

and Pharming Group NV today announced that retrospective analyses of integrated efficacy data and immuno-safety data were presented in two oral presentations at the 2011 Biennial Meeting of the World Allergy Congress in Cancun, Mexico on December 6, 2011. The data analyzed are from placebo-controlled and open-label clinical studies conducted with the investigational drug RHUCIN® (recombinant human C1 inhibitor, or C1INH) in patients with hereditary angioedema.